All In Biotech

Drug Trial Radar · NCT04632966

Safety Study of PTP-001 for Treating Knee Osteoarthritis

A Prospective, Open-Label, Dose-Escalation Phase 1 Study of Intra-Articular Administration of an Allogeneic Human Placental Tissue Particulate (PTP-001) for the Treatment of Knee Osteoarthritis

Last checked: Nov 19, 2026Latest source record: Dec 22, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

20

Actual

Start

Feb 26, 2021

Primary completion

Sep 2022

Study completion Dec 2022

Sponsor

Lead sponsor
Bioventus LLCIndustry
Sponsor type
Industry
First posted
Nov 17, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 40 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Evaluation of safety, tolerability, and efficacy of a single intra-articular (IA) injection of PTP-001, an allogeneic placental tissue particulate, in individuals with knee osteoarthritis (OA).

Conditions

  • Knee Osteoarthritis

Interventions

  • Biological: PTP-001Biological

    allogeneic placental tissue particulate

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of local and systemic treatment emergent adverse events (AEs) and incidence of abnormal laboratory and immunogenicity panelsTime frame: Baseline to Week 52

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • James R. Urbaniak, MD, Duke Sports Science Institute

    Durham, North Carolina

  • Coastal Carolina Research Center

    North Charleston, South Carolina

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.